BioHarvest Sciences CEO reflects on milestone year in shareholder letter

BioHarvest closed 2025 with an annualized revenue run rate exceeding US$36 million and gross margins above 60%, driven by its VINIA D2C business (over 85,000 active users, >90% subscription penetration) and early traction in its CDMO unit. The company launched a VINIA Blood Flow Hydration product, reported strong customer reviews and market positioning, and said CDMO partnerships (including a saffron-derived program with Saffron Tech) validate its Botanical Synthesis platform. Management raised roughly $30.8 million in 2025 via warrant exercises, debt conversions and an oversubscribed institutional equity financing, plans a 100-ton manufacturing footprint, and enters 2026 fully funded while targeting accelerating revenue growth, expanding margins and adjusted EBITDA breakeven.

Analysis

Market structure: BioHarvest (BHST) is the primary beneficiary — D2C subscription economics (85k active users, >90% subscription) and a nascent CDMO with higher-ticket B2B contracts create two distinct monetization engines. Incumbent raw-material suppliers (saffron/fragrance extractors) and resveratrol commodity plays are the likely losers if BioHarvest scales plant‑synthesis at lower marginal cost. Expect upward pricing power in niche botanicals and downward pressure on spot prices for scarce botanicals; BHST equity will see greater idiosyncratic volatility and options IV expansion versus broad consumer names like AMZN.

Risk assessment: Tail risks include regulatory action on health claims (FDA/FTC), a major CDMO client pull‑out, and dilution from future financings despite $30.8M raised; each could erase >50% of equity value in a downside scenario. Timeframe: immediate (0–90 days) sensitivity to VINIA Blood Flow early sales and ad‑spend ROI, short‑term (3–12 months) hinge on CDMO contract milestones and capacity buildout execution, long term (12–36 months) on adjusted EBITDA breakeven. Hidden dependency: >90% subscription purchases concentrate churn/CAC risk — a 10–20% annualized churn upsizes cash burn materially.

Trade implications: Establish a tactical 2–3% long in BHST (12‑month horizon) and size a 0.5–1% long 9–12 month call-debit spread to capture rerating while capping premium; add on quarterly beats (revenue run-rate sustaining >$36M or CDMO revenue growth >30% QoQ). Pair trade: long BHST vs short HIMS (HIMS) 0.5:0.5 to isolate D2C execution risk (HIMS has higher marketing spend and lower gross margin); set stop-loss at 30% on BHST and take-profit tranche at +50% within 6–12 months.

Contrarian angles: The market may underappreciate CDMO margin potential — if CDMO revenues exceed Product revenues within 12 months (management target), valuation multiples could expand 2x. Conversely, consensus may be complacent on churn and CAC: a 20%+ increase in CAC from aggressive ad spend would defer breakeven and justify >40% downside. Watch customer concentration on CDMO contracts and Saffron Tech milestones as binary catalysts that will fast‑track either rerating or de‑risking.

Key Decisions for Investors

• Establish a 2–3% long position in BHST (BioHarvest Sciences) with a 12‑month horizon; add a second tranche only after two consecutive quarters showing revenue run-rate >= $36M sustained and CDMO revenue growth >25% QoQ. Set an initial stop-loss at -30% and take-profit tranche at +50% within 6–12 months.
• Buy a 9–12 month BHST call debit spread sized 0.5–1% notional (long lower strike, sell higher strike) to capture upside if VINIA Blood Flow ad spend scales while capping premium; roll or unwind if implied volatility rises >40% above current level or if churn exceeds 20% annualized.
• Execute a relative-value pair: long BHST vs short HIMS (HIMS) sized 0.5:0.5 to isolate D2C execution; close if the pair diverges by >30% or if HIMS reports significantly better-than-expected margin improvement. Monitor quarterly CAC and subscription churn metrics (trigger: churn >20% or CAC growth >25% YoY) — reduce BHST exposure if triggered.